Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: A phase II trial of the Gynecologic Oncology Group

1989 ◽  
Vol 29 (3) ◽  
pp. 282-282
Author(s):  
JT Thigpen ◽  
JA Blessing ◽  
H Ball ◽  
P Hanjani ◽  
A Manetta ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
First Line ◽  
Recurrent Carcinoma ◽  
Line Chemotherapy

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study.

1991 ◽  
Vol 9 (11) ◽  
pp. 1962-1966 ◽  
Author(s):  
J T Thigpen ◽  
J A Blessing ◽  
J Beecham ◽  
H Homesley ◽  
E Yordan
Keyword(s):  
Phase Ii Trial ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
First Line ◽  
Uterine Sarcomas ◽  
Oncology Group Study ◽  
Prior Chemotherapy ◽  
Life Threatening ◽  
Line Chemotherapy

Ninety-six assessable patients with advanced or recurrent uterine sarcomas, who were no longer controllable with surgery and radiotherapy, and who had not received prior chemotherapy were treated with cisplatin 50 mg/m2 intravenously every 3 weeks. Of 63 cases with mixed mesodermal tumors, five complete responses (CRs; 8%) and seven partial responses (PRs; 11%) were observed (95% confidence interval [CI], 10.3% to 30.9%). Of 33 patients with leiomyosarcoma, one PR (3%) was observed (95% CI, .1% to 15.8%). Adverse effects included leukopenia (23%), nausea and vomiting (73%), and mild azotemia (42%). No patients experienced life-threatening toxicity. Cisplatin has definite activity when given at the dose and schedule that we tested for patients with mixed mesodermal sarcomas who have not received prior chemotherapy, but has little activity in patients with leiomyosarcoma.

Sign in / Sign up

Export Citation Format

Share Document